Accoridng to the latest reports, this has not been a bad year for AstraZeneca’s sales. Check out the details about their quarterly report below.
AstraZeneca’s quarterly estimates
The firm seems to have raised its full-year adjusted earnings forecast after third-quarter profit and revenue topped analysts’ expectations. The massive numbers have been helped by sales of its key cancer drugs.
Just in case you did not know this, oncology is AstraZeneca’s biggest disease area. Their cancer drugs accounted for close to 36% of the London-listed drugmaker’s total product sales last year.
According to the reports coming from Investing.com, the “sales of AstraZeneca’s key cancer medicines — Tagrisso and Imfinzi — helped the company’s quarterly revenue beat, with sales of its broader oncology portfolio rising 24%.”
The same notes revealed the following data:
“Tagrisso generated nearly $1.4 billion, Imfinzi brought in $737 million in the quarter. Cowen analysts had forecast their sales at about $1.35 billion and $725 million, respectively.”
It’s also worth noting the fact that the label expansions for a handful of cancer drugs – Tagrisso, Imfinzi, Lynparza and Enhertu – have driven prescription growth, noted Citeline analyst Zhyar Said.
“Whilst some of the other key players in the COVID-19 market started to show a decline in momentum, AstraZeneca’s diversified portfolio…has allowed them to stay on top and not be affected by the reduced global uptake of vaccines,” Said added.
AstraZeneca in the news
The firm has been making headlines in relation to covid vaccines as well, as we reported earlier today.
It’s been just reported that AstraZeneca is no longer pursuing U.S. approval of its COVID-19 vaccine, Chief Executive Pascal Soriot said in a media call on Thursday.
Demand for vaccines in the country is declining and the market is well served by the mRNA shots, he said, according to the same reports. Check out more details in our previous article.
